Sulfachrysoidine is a sulfamylchrysoidine derivative and lipid-soluble azo dye with antibacterial activity.

Litronesib is a specific, ATP-uncompetitive, allosteric, and potent small-molecule inhibitor of Eg5 with potential antineoplastic activity. Litronesib selectively inhibits the activity of Eg5, which may result in mitotic disruption, apoptosis and consequently cell death in tumor cells that are actively dividing. Histone-H3 phosphorylation of tumor and proliferating skin cells is a promising pharmacodynamic biomarker for in vivo anticancer activity of litronesib. Litronesib had been in phase I clinical trial for the treatment of solid tumors. The most frequent-related adverse events were hematologic such as neutropenia.

Metethoheptazine (WY-535) is an analgesic agent.

Neocinchophen is an analgesic and uricosuric. Cinchophen and neocinchophen (introduced by Chemische Fabrik auf Aktien as Atophan and Novatophan) were being advertised as superior substitutes for salicylates in the treatment of rheumatic fever. Chemically, cinchophen is phenylcinchoninic acid, and neocinchophen is the ethyl ester of its methyl derivative.

KW-2449, a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase, is under investigation to treat leukaemia patients. KW-2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase with IC50 values of 6.6nM, 14nM, 4nM and 48nM, respectively. KW-2449 has potent growth inhibitory activity against various types of leukaemia by several mechanisms of action. Kyowa Hakko Kirin Pharma Inc. (a US subsidiary of Kyowa Hakko Kirin Co) was developing KW-2449 for the treatment of acute lymphoblastic leukaemia; acute myeloid leukaemia; chronic myeloid leukaemia; myelodysplastic syndromes, but later these studies were discontinued.

Doliracetam possesses activity on the central nervous system. It has cognition enhancing properties and might be useful in the treatment of Alzheimer’s disease and epilepsy

Vicriviroc or SCH 417690 is a potent and selective antagonist of the CCR5 receptor. vicriviroc binds specifically to the CCR5 receptor and prevents infection of target cells by CCR5-tropic HIV-1 isolates. In antiviral assays, vicriviroc showed potent, broad-spectrum activity against genetically diverse and drug-resistant HIV-1 isolates and was consistently more active than SCH-C in inhibiting viral replication. This compound demonstrated synergistic anti-HIV activity in combination with drugs from all other classes of approved antiretrovirals. Competition binding assays revealed that vicriviroc binds with higher affinity to CCR5 than SCH-C. Functional assays, including inhibition of calcium flux, guanosine 5'-[35S]triphosphate exchange, and chemotaxis, confirmed that vicriviroc acts as a receptor antagonist by inhibiting signaling of CCR5 by chemokines. Finally, vicriviroc demonstrated diminished affinity for the human ether a-go-go related gene transcript ion channel compared to SCH-C, suggesting a reduced potential for cardiac effects. Vicriviroc represented a promising new candidate for the treatment of HIV-1 infection. Vicriviroc for HIV treatment was previously in Phase III studies but has since been discontinued.

Clotioxone is a fungicide compound for the use in agriculture, developed by a French company Rhone-Poulenc in the 1960s.

Delfaprazine is an antidepressant drug, synthesized at the Spanish Centro de Investigacion, Grupo Ferrer S.A. Toxicological study in rats, rabbits, and dogs have shown that delfaprazine has less cardiotoxic side effects.

Enviradene (LY 127123) is a benzimidazole antiviral compound. It inhibited picornavirus replication and infection in vitro.